Senti Biosciences (SNTI) Competitors $1.69 -0.21 (-11.05%) Closing price 04:00 PM EasternExtended Trading$1.81 +0.12 (+7.10%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI vs. BTMD, CYBN, NKTX, ONCY, SAVA, FATE, CLYM, PYXS, IVVD, and GLSIShould you be buying Senti Biosciences stock or one of its competitors? The main competitors of Senti Biosciences include biote (BTMD), Cybin (CYBN), Nkarta (NKTX), Oncolytics Biotech (ONCY), Cassava Sciences (SAVA), Fate Therapeutics (FATE), Climb Bio (CLYM), Pyxis Oncology (PYXS), Invivyd (IVVD), and Greenwich LifeSciences (GLSI). These companies are all part of the "pharmaceutical products" industry. Senti Biosciences vs. Its Competitors biote Cybin Nkarta Oncolytics Biotech Cassava Sciences Fate Therapeutics Climb Bio Pyxis Oncology Invivyd Greenwich LifeSciences Senti Biosciences (NASDAQ:SNTI) and biote (NASDAQ:BTMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings. Which has more volatility and risk, SNTI or BTMD? Senti Biosciences has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500. Comparatively, biote has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Do analysts prefer SNTI or BTMD? Senti Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 402.96%. biote has a consensus target price of $6.00, indicating a potential upside of 116.61%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33biote 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media prefer SNTI or BTMD? In the previous week, Senti Biosciences and Senti Biosciences both had 3 articles in the media. Senti Biosciences' average media sentiment score of 0.63 beat biote's score of -0.20 indicating that Senti Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Senti Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive biote 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings & valuation, SNTI or BTMD? biote has higher revenue and earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSenti Biosciences$2.56M17.27-$52.79M-$8.95-0.19biote$197.19M0.69$3.16M$0.903.08 Do insiders & institutionals believe in SNTI or BTMD? 25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 21.7% of biote shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 24.0% of biote shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is SNTI or BTMD more profitable? biote has a net margin of 15.73% compared to Senti Biosciences' net margin of 0.00%. biote's return on equity of -21.00% beat Senti Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Senti BiosciencesN/A -223.98% -76.02% biote 15.73%-21.00%18.26% Summarybiote beats Senti Biosciences on 8 of the 15 factors compared between the two stocks. Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNTI vs. The Competition Export to ExcelMetricSenti BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.70M$3.38B$6.12B$10.63BDividend YieldN/A2.29%5.66%4.71%P/E Ratio-0.197.8864.0822.83Price / Sales17.27462.21612.79132.68Price / CashN/A47.2238.5062.09Price / Book0.3210.2112.726.53Net Income-$52.79M-$52.40M$3.30B$275.96M7 Day Performance5.62%0.88%1.05%-1.40%1 Month Performance30.00%12.35%7.56%5.16%1 Year Performance-19.91%30.13%79.69%31.55% Senti Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNTISenti Biosciences2.4 of 5 stars$1.69-11.1%$8.50+403.0%-12.8%$49.70M$2.56M-0.194Analyst ForecastBTMDbiote2.3168 of 5 stars$2.98-0.3%$6.00+101.3%-45.6%$147.33M$199.07M3.31194News CoverageAnalyst DowngradeCYBNCybinN/A$5.85-2.4%$85.00+1,354.2%N/A$147.22MN/A-1.3350NKTXNkarta2.3437 of 5 stars$2.07-0.2%$13.60+558.6%-40.1%$145.26MN/A-1.38140News CoverageAnalyst ForecastONCYOncolytics Biotech1.9125 of 5 stars$1.39-1.8%$5.00+261.0%-5.3%$139.00MN/A-5.1330News CoverageAnalyst ForecastSAVACassava Sciences2.5022 of 5 stars$2.88-8.4%$2.00-30.4%-83.2%$138.89MN/A-1.1330Analyst ForecastFATEFate Therapeutics3.881 of 5 stars$1.19+18.5%$3.30+178.5%-46.5%$137.82M$13.63M-0.82550Analyst ForecastHigh Trading VolumeCLYMClimb Bio3.979 of 5 stars$2.00+0.5%$9.25+362.5%N/A$135.52MN/A-2.869Analyst ForecastShort Interest ↓PYXSPyxis Oncology1.8937 of 5 stars$2.19-0.7%$7.75+254.7%+21.6%$135.51M$2.82M-1.3760News CoverageAnalyst ForecastGap UpIVVDInvivyd3.4817 of 5 stars$1.11-1.3%$3.18+188.1%+109.7%$132.76M$46.21M-1.20100Analyst ForecastAnalyst RevisionGap UpGLSIGreenwich LifeSciences1.0975 of 5 stars$9.74-4.2%$42.00+331.4%-13.7%$132.76MN/A-7.163 Related Companies and Tools Related Companies biote Alternatives Cybin Alternatives Nkarta Alternatives Oncolytics Biotech Alternatives Cassava Sciences Alternatives Fate Therapeutics Alternatives Climb Bio Alternatives Pyxis Oncology Alternatives Invivyd Alternatives Greenwich LifeSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNTI) was last updated on 10/10/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
